[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-436848-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-436848-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","neoadjuvant-therapy-editorial","Neoadjuvant therapy - Editorial","","Neoadjuvant therapy aims to improve cancer outcomes while preserving organs and maintaining post-treatment quality of life through accurate pretherapy evaluation and personalized treatment planning. The editorial discusses evidence from a Journal of the Chinese Medical Association study examining whether adding mitomycin-C to neoadjuvant concurrent chemoradiotherapy benefits advanced-stage rectal adenocarcinoma patients. Results suggest improved tumor downstaging and favorable disease-free and overall survival trends, alongside increased low-grade toxicity, emphasizing careful patient selection and further discussion.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/neoadjuvant-therapy-editorial/436848/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/neoadjuvant-therapy-editorial/436848.png","ImageObject",300,407,{"name":42,"@type":43},"Aditya","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-07","2026-09-29",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main therapeutic goal of neoadjuvant therapy discussed in the editorial?","Question",{"text":63,"@type":64},"To achieve lifesaving cancer control while also optimizing post-treatment recovery, organ preservation, and quality of life through precise evaluation and personalized planning.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What treatment strategy does the editorial focus on from the referenced rectal cancer study?",{"text":68,"@type":64},"Neoadjuvant concurrent chemoradiotherapy (NAT-CCRT) with the addition of mitomycin-C, compared with NAT-CCRT alone, for advanced-stage rectal adenocarcinoma.",{"name":70,"@type":61,"acceptedAnswer":71},"What benefits and risks does the editorial highlight for the mitomycin-C plus NAT-CCRT approach?",{"text":72,"@type":64},"The approach shows a favorable trend toward tumor downstaging and improved disease-free and overall survival rates, but it is associated with increased low-grade toxicity, especially neutropenia and certain adverse events.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},436848,1790951628,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":26,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":97,"preview_page_count":4},962085564549,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","J Chin MedAssoc  \nEditorial  \nNeoadjuvant therapy  \nPeng-Hui Wanga,b,c,d,*, Szu-Ting Yanga,b,c, Chia-Hao Liua,b,c  \naDepartment of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC; bInstitute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC; cFemale Cancer Foundation, Taipei, Taiwan, ROC; dDepartment of Medical Research, China Medical University Hospital, Taichung, Taiwan, ROC  \nMalignant diseases are the leading cause of death in Taiwan.1 Life-saving is the most critical issue for cancer treatment; however, the patients not only wish to be cured from the diseases but also want to have a good to excellent posttreatment recovery as well as had better have their organ-preservation or complete return of the function to maintain good quality of life (QoL) in their remaining life, and these wishes now have become an optimal therapeutic goal for both physicians and patients.2–4 An accurate and precise pretherapy evaluation and an appropriate and personalized therapeutic plan for these cancer or critically ill patients through the far-advanced development of new technology or therapeutic strategy, such as a minimally traumatic organ-preservation approach and a method for maintenance of physiological and morphological function of targeted lesions can minimize the risk of overtreatment and subsequently avoid the development of severe posttherapy sequelae without compromising the therapeutic efficacy.5–7 To reach this goal, it is still challengeable. The recent publication in the Journal of the Chinese Medical Association entitled “The effect of Mitomycin-C in neoadjuvant concurrent chemoradiotherapy for rectal cancer”may be an example, since the authors investigated the possible benefit of using neoadjuvant therapy (NAT) using concurrent chemoradiotherapy (CCRT), called NAT-CCRT with adding mitomycin-C (called MMT+NAT-CCRT) in the management of patients with clinical T3, T4 or node-positive rectal adenocarcinoma staged (advanced-stage rectal cancer) by magnetic resonance image (MRI) or computed tomography (CT) compared to the NAT-CCRT group.8  \nThe authors retrospectively enrolled 191 patients receiving NAT-CCRT (radiotherapy [RT] plus [+] oral tegafur-uracil [UFUR]) and 195 patients fulfilling the above-mentioned criteria (MMC+NAT-CCRT) .8 The authors found that the MMC+NATCCRT group had a marginally increased effect to downstage of advanced rectal cancer with odd ratio (OR) of 1.52 (95%  \n*Address Correspondence. Dr. Peng-Hui Wang, Department of Obstetricsand Gynecology, Taipei Veterans General Hospital, 201, Section 2, Shi-Pai Road, Taipei 112, Taiwan, [ROC. E-mail addresses: phwang@vghtpe.gov.tw](ROC. E-mail addresses: phwang@vghtpe.gov.tw); [pongpongwang@gmail.com](pongpongwang@gmail.com) (P.-H. Wang).  \nConflicts of interest: Dr. Peng-Hui Wang, an editorial board member at Journal of the Chinese Medical Association, had no role in the peer review process of or decision to publish this article. The other authors declare that they have no conflicts of interest related to the subject matter or materials discussed in this article.  \nJournal of Chinese Medical Association. (2023) 86: 133-134.  \nReceived November 20, 2022; accepted November 21, 2022.  \ndoi: 10. 1097/JCMA.0000000000000855.  \nCopyright © 2023, the Chinese Medical Association. This is an open access article under the CC BY-NC-ND license ([http://creativecommons.org/licenses/](http://creativecommons.org/licenses/)[ ](http://creativecommons.org/licenses/)[by-nc-nd/4.0/](by-nc-nd/4.0/))  \n[www.ejcma.org](www.ejcma.org)  \nconfidence interval [CI], 0.99, 2.35) .8 Additionally, the authors found downstage of these patients showed a strongly favorable effect on both disease-free survival (DFS, OR 2 .2; 95% CI, 1 .53, 3. 1) and overall survival rates (OS, OR, 1.73; 95% CI, 1.23, 2.43), although this MMC+NAT-CCRT treatment was associated with an increased low-grade toxicity, particularly neutropenia, genitourinary ","cbCairZcZXaqlEvN","https://ap.wps.com/l/cbCairZcZXaqlEvN","pdf",291242,"English","# Neoadjuvant therapy\n## Treatment goals and need for personalized planning\n## NAT-CCRT with mitomycin-C: evidence and outcomes\n## Survival effects, toxicity concerns, and patient selection","[{\"question\":\"What is the main therapeutic goal of neoadjuvant therapy discussed in the editorial?\",\"answer\":\"To achieve lifesaving cancer control while also optimizing post-treatment recovery, organ preservation, and quality of life through precise evaluation and personalized planning.\"},{\"question\":\"What treatment strategy does the editorial focus on from the referenced rectal cancer study?\",\"answer\":\"Neoadjuvant concurrent chemoradiotherapy (NAT-CCRT) with the addition of mitomycin-C, compared with NAT-CCRT alone, for advanced-stage rectal adenocarcinoma.\"},{\"question\":\"What benefits and risks does the editorial highlight for the mitomycin-C plus NAT-CCRT approach?\",\"answer\":\"The approach shows a favorable trend toward tumor downstaging and improved disease-free and overall survival rates, but it is associated with increased low-grade toxicity, especially neutropenia and certain adverse events.\"}]","Neoadjuvant therapy - Editorial | PDF",1790679222]